Ascletis Pharma, Inc. (HK:1672) has released an update.
Ascletis Pharma Inc. has issued a profit warning, anticipating a significant net loss of RMB127.3 million to RMB132.3 million for the first half of 2024, compared to RMB16.6 million in the same period of 2023. The decline is attributed to the decreased market demand for their ritonavir product due to effective COVID-19 control in mainland China and increased research and development costs. Investors are advised to exercise caution and await the finalized interim results due in late August 2024.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.
